Abstract
There is no clear standard therapy for patients with radioactive iodine (131I)-refractory locally advanced or metastatic differentiated thyroid cancer. The therapeutic options for this indication have expanded with the recently approved multiple kinase inhibitor sorafenib. Recommendations for the definition and the management of iodine refractory patients were worked up by an interdisciplinary expert panel, consisting of endocrine surgeons, medical oncologists and nuclear medicine specialists.
Keywords:
Radioactive iodine-refractoriness; sorafenib; thyroid cancer.
MeSH terms
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents / adverse effects
-
Chemoradiotherapy / standards
-
Evidence-Based Medicine
-
Germany
-
Humans
-
Iodine Radioisotopes / therapeutic use*
-
Medical Oncology / standards
-
Niacinamide / administration & dosage
-
Niacinamide / adverse effects
-
Niacinamide / analogs & derivatives*
-
Phenylurea Compounds / administration & dosage*
-
Phenylurea Compounds / adverse effects
-
Practice Guidelines as Topic*
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / adverse effects
-
Radiopharmaceuticals / therapeutic use
-
Sorafenib
-
Thyroid Neoplasms / diagnosis*
-
Thyroid Neoplasms / therapy*
-
Treatment Failure
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Iodine Radioisotopes
-
Phenylurea Compounds
-
Protein Kinase Inhibitors
-
Radiopharmaceuticals
-
Niacinamide
-
Sorafenib